top of page

The StiRx Mission

Our mission is to empower sexual health for all people.  We aim to accomplish this by developing best-in-class vaccines and biologicals against the most severe sexually transmitted infections.  Our vision is to reduce mortality and morbidity caused by STIs with the use of our tools, including significant reduction in antibiotic microbial resistance of currently available drugs.


Identifying the Problem

STIs are a global threat. They affect every community and every country, rich and poor, privileged and underprivileged. Currently the only available tool to combat STIs is antibiotics, to which many of these infections continue to grow more resistant. Year after year, even throughout the Covid-19 lockdowns, the rate of STI cases continues to rise.


Globally there are:

• Estimated 129 million new chlamydia cases per year

• Estimated 82 million new gonorrhea cases per year

• Estimated 7.1 million new syphilis cases per year

• Estimated 156 million new trichomoniasis cases per year

Founding Team

The StiRx founders are a team of experienced leaders with scientific and business expertise.


Davinder Gill, PhD

25+ years of commercial experience ex-CEO Merck/Wellcome Hilleman Laboratories, Global VP Pfizer, Executive at Wyeth and Millennium


Sanjay Ram, MBBS

25+ years clinical and academic research Professor, University of Massachusetts Chan Medical School, Member of the American Society of Clinical Investigation, Fellow of the American Academy of Microbiology


Peter Rice, MD

40+ years clinical and academic research Professor of Medicine, Fellow of the American Academy of Microbiology, former NIH/NIAID MERIT awardee, University of Massachusetts Chan Medical School, former Chief of infectious diseases Boston University

Scientific Advisory Board


Toni Darville, MD

Distinguished Professor of Pediatrics and Microbiology & Immunology Chief, Pediatric Infectious Disease Vice Chair of Pediatric Research Scientific Director, Children’s Research Institute Co-Director, Medical Science Training Program University of North Carolina at Chapel Hill


Caroline E. Cameron, PhD

Professor, Department of Biochemistry and Microbiology, University of Victoria

Affiliate Professor, Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington


Anna Wald, MD, MPH

Head of Allergy and Infectious Diseases Division, Professor of Medicine, Laboratory Medicine & Pathology, & Epidemiology, University of Washington Professor, Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center


Steven Projan, PhD, FAAM

Former Senior V.P. R&D; iMed Head Infectious Disease and Vaccines, MedImmune Vice President, Global Head Infectious Diseases, Novartis Vice President and Head, Biological Technologies, Wyeth Research


George Siber, MD

Former Harvard professor, current adjunct professor at Johns Hopkins University and professor at the University of Massachusetts Medical School, former executive vice president and chief science officer of Wyeth, and advisory committee member of the World Health OrganizationUS National Institutes of HealthGates Foundation, and the National Institute of Allergy and Infectious Diseases.

Kenneth Simmen, PhD

Senior executive with 30 years of global experience in drug discovery/early clinical
development and innovative dealmaking within infectious diseases & vaccines at J&J.
Played key role in invention and development of Hepatitis C virus antiviral product
Simeprevir (OLYSIO)

bottom of page